Celecoxib/olmesartan - Marina Biotech

Drug Profile

Celecoxib/olmesartan - Marina Biotech

Alternative Names: IT-103

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator IthenaPharma
  • Developer Marina Biotech
  • Class Analgesics; Antihypertensives; Imidazoles; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Inflammation
  • Preclinical Arthritis; Cancer; Hypertension; Pain

Most Recent Events

  • 29 Mar 2017 Preclinical trials in Arthritis in USA prior to March 2017 (unspecified route)
  • 29 Mar 2017 Preclinical trials in Hypertension in USA prior to March 2017 (unspecified route)
  • 29 Mar 2017 Preclinical trials in Pain in USA prior to March 2017 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top